February 26, 2024 BERN, Switzerland, and BOSTON — Ikerian AG and RetinAI Inc. US, a developer of software solutions for image processing and artificial intelligence (AI) in ophthalmology, has launched RetinAI Discovery for Clinics, with
February 22, 2024 NEW YORK, N.Y. – A large language model (LLM) artificial intelligence (AI) system can match, or in some cases outperform, human ophthalmologists in the diagnosis and treatment of patients with glaucoma and
February 21, 2024 MASSAPEQUA PARK, N.Y. — The Ocular Wellness and Nutrition Society (OWNS), a nonprofit organization dedicated to advancing eye health through nutrition and wellness, has announced the next phase expansion of its advisory
February 14, 2024 LONDON and NEW YORK – OKYO Pharma Limited has announced that the U.S. Food and Drug Administration (FDA) has cleared OK-101 as its first Investigational New Drug (IND) application for the treatment
February 14, 2024 BEDFORD, Mass. — Ocular Therapeutix, Inc. has announced that the first three subjects have been screened and received their first aflibercept injection in the Phase 3 SOL-1 clinical trial of AXPAXLI (axitinib intravitreal implant, also known
February 14, 2024 LONDON and NEW YORK — MeiraGTx Holdings, a vertically integrated, clinical stage gene therapy company, announced the achievement of the first milestone payment of $50 million under the asset purchase agreement the company entered
February 13, 2024 NEW YORK— Eyenovia, Inc. has announced that the company’s facility in Redwood City, Calif., successfully completed FDA inspection for approval as a commercial manufacturing facility. The Redwood City facility will primarily be
February 1, 2024 IRVINE, Calif., and COLORADO SPRINGS, Colo., — OcuLenz, the new AR/XR headset from Ocutrx Technologies, Inc., is set for commercial release in the first half of this year. The headset has been
February 1, 2024 CHICAGO — Prevent Blindness has declared February as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month. The group is offering a variety of free educational resources to the public and professionals, including fact
January 26, 2024 DES MOINES, Iowa – Kemin Industries, a global ingredient manufacturer, was highlighted in a published study on the efficacy of spearmint extract for nutritional support in neural tissues in a model of hypertensive
January 19, 2024 LAS VEGAS — Visioneering Technologies, Inc. has reported the results of its Defocus Curve study with mature presbyopes, a prospective, non-dispensing, single-masked (subject) study conducted at four clinical sites. The study evaluated
January 11, 2024 Visioneering Technologies Inc. (VTI) and Jobson Publishing have collaborated on a new 14-page e-publication, Redefine What’s Possible, which features articles about the growing presbyopia population and the innovative solutions that NaturalVue Enhanced
January 10, 2024 LONDON and NEW YORK — OKYO Pharma Limited reports positive safety and efficacy results in its Phase 2, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of OK-101 ophthalmic solution in
January 5, 2024 VAUGHAN, Ontario – Bausch + Lomb Corporation and Glaucoma Research Foundation (GRF) have launched “Faces of Glaucoma,” a campaign that will highlight diverse patient stories and raise awareness of the second leading
January 4, 2024 NASHVILLE, Tenn. — Harrow announced that it has partnered with three leading health care technology platforms to expand U.S. availability of VEVYE (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) dosed,
January 2, 2024 CHICAGO — Prevent Blindness is once again participating in January’s National Glaucoma Awareness Month to provide patients, care partners, and professionals with a variety of helpful resources to educate on glaucoma, one
December 18, 2023 As a health care provider, how good are you at staying up to date with your own health screenings? Share with us in the following poll from our sister publications, Women In
December 18, 2023 YAVNE, Israel – The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for BELKIN Vision’s glaucoma laser, the Eagle device, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser. The Eagle is
December 15, 2023 ALISO VIEJO, Calif. — Glaukos Corporation announced the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for a single administration per eye of iDose TR (travoprost intracameral
December 8, 2023 Research funded by the National Eye Institute suggests that low density of pigment in the macula is associated with thinning of the retina and may serve as an early warning sign of
December 1, 2023 CHICAGO —Prevent Blindness is announcing the third annual Geographic Atrophy (GA) Awareness Week as Dec. 4-10, 2023. More than eight million people in the world have GA, with an estimated 1 million
December 1, 2023 The webinar “Comprehensive Patient Care: Why Nutrition Matters Now More Than Ever” is now available on demand (access below). It’s part of Jobson Medical Information’s Ocular Health & Wellness Education Initiative, which
November 28, 2023 SAN DIEGO and SOUTH SAN FRANCISCO – LENZ Therapeutics and Graphite Bio, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The
November 13, 2023 WEEHAWKEN, N.J. — The 2023 Collaborative Care Symposium will be held December 2-3 at the EnVue Hotel in Weehawken, New Jersey, and registration is open now. The event, “Better Together: A Unified Approach to
November 10, 2023 YOKNE’AM ILLIT, Israel, — Lumenis has announced the launch of OptiPLUS, the first dual frequency radiofrequency (RF) device on the market. It delivers heat across different tissue layers, increasing blood circulation to promote medical performance and aesthetic results.1 OptiPLUS is a complementary device to Lumenis’ novel OptiLIGHT technology, which targets
November 10, 2023 VAUGHAN, Ontario – Bausch + Lomb Corporation has announced the U.S. launch of SeeNa, an ophthalmic diagnostic system for refractive cataract patients that is fully integrated with Bausch + Lomb’s Eyetelligence surgical planning software
November 8, 2023 WALTHAM, Mass. — Apellis Pharmaceuticals, Inc. has announced data from the GALE extension study following three years of continuous treatment with SYFOVRE (pegcetacoplan injection), the first-ever FDA-approved treatment for geographic atrophy (GA) secondary
November 7, 2023 FARMINGTON HILLS, Mich — Ocuphire Pharma, Inc. has announced the appointment of George Magrath, MD, MBA, MS, as chief executive officer and member of the board of directors, effective Nov. 1. Dr.
November 3, 2023 NEW YORK — Eyenovia, Inc., announced that the FDA has approved Eyenovia’s Supplemental New Drug Application (sNDA), adding Coastline International as a contract manufacturer. Coastline will manufacture cartridge subassemblies for Mydcombi, the only FDA-approved
November 3, 2023 ALPHARETTA, Ga. — Clearside Biomedical, Inc. has announced the completion of recruitment in its ODYSSEY Phase 2b clinical trial, a randomized, double-masked, parallel-group, active-controlled, multi-center study in participants with neovascular age-related macular
November 1, 2023 WASHINGTON, D.C. — Nominations for the inaugural Contact Lens Institute (CLI) Culture Awards are now being accepted through Nov. 30. The program honors eye care professionals who foster a positive contact lens
November 1, 2023 Jobson Medical Information has the launched the Ocular Health & Wellness Education Initiative, consisting of a comprehensive eResource and CE webinar. “Ocular Health and Wellness: It’s Evidence Based,” features articles by leaders
October 31, 2023 VAUGHAN, Ontario – Bausch + Lomb Corporation has launched the enVista Aspire monofocal and toric intraocular lenses (IOLs) with Intermediate Optimized (IO) optics in the United States. enVista Aspire combines novel optics,
October 25, 2023 ATLANTA – Bruder Healthcare, a Hilco Vision Company, has announced the addition of an on-the-go, single-use, moist heat eye mask, Eyedration by Bruder, for those suffering from dry, tired eyes. The mask,
October 19, 2023 PONTE VEDRA, Fla. — Orasis Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. Qlosi is
October 18, 2023 NEW YORK — The Ocular Wellness and Nutrition Society (OWNS), a leading organization dedicated to advancing ocular health through nutrition and wellness, has announced a significant expansion of its leadership team with
October 13, 2023 VAUGHAN, Ontario — Bausch + Lomb Corporation has announced the U.S. launch of Lumify Eye Illuminations, a new line of hypoallergenic specialty eye care products scientifically developed to cleanse, nourish and brighten the sensitive eye
October 11, 2023 WALTHAM, Mass. — Thea Pharma Inc. announced the launch and availability of Iyuzeh (latanoprost ophthalmic solution) 0.005% in the U.S. market. Preservative-free latanoprost, launched over 10 years ago, is available in 46
September 28, 2023 OCULUS, Inc. has announced a strategic partnership with LUVO to bring new specialty care devices to the U.S. optometry and ophthalmology market. This partnership serves to equip eye care practitioners with the
September 14, 2023 VAUGHAN, Ontario — Bausch + Lomb Corporation has announced the U.S. commercial launch of Miebo (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease (DED). Miebo is the
August 8, 2023 TOKYO — Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
August 1, 2023 CHESTERFIELD, Mo. — EyePromise has announced the latest addition to its comprehensive nutritional system for eye care practices. The new Zx Pro offers the latest in biomarker technology and allows eye care
July 25, 2023 IRVINE, Calif. — Tarsus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of demodex blepharitis. XDEMVY, formerly known as TP-03,
July 18, 2023 NASHVILLE, Tenn. — Harrow Health, Inc. has announced agreements with affiliates of Santen Pharmaceutical Co., Ltd., under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded
July 19, 2023 LIÈGE, Belgium – BVI Medical Inc. has opened a new facility here to increase its intraocular lens (IOL) production capacity. This results in a sizeable increase in BVI’s IOL production capacity, unlocking
July 18, 2023 NASHVILLE, Tenn. and HEIDELBERG, Germany — Harrow and Novaliq GmbH announced an agreement under which Harrow will acquire the U.S. and Canadian commercial rights for VEVYE (cyclosporine ophthalmic solution) 0.1%, a patented,
July 11, 2023 NEW YORK—The adoption of telemedicine has shown an increase in eye care, particularly during the COVID-19 pandemic. Jobson Research’s recent Telemedicine Research report focuses on the integration of telemedicine into contact lens care,
July 6, 2023 BRIDGEWATER, N.J. – RVL Pharmaceuticals has launched ELEVATE, a first-of-its-kind, proprietary prescription e-commerce platform. This platform aligns with RVL’s vision of seamlessly integrating its products into customers’ practices while further enhancing patient
July 6, 2023 VAUGHAN, Ontario — With the recent announcements of acquisitions of XIIDRA and Blink following the FDA approval of Miebo, Bausch + Lomb Corp. has substantially and quickly expanded its dry eye offerings.
June 5, 2023 VAUGHAN, Ontario — Bausch + Lomb Corporation announced the U.S. launch of Bausch + Lomb INFUSE Multifocal silicone hydrogel (SiHy) daily disposable contact lenses. Featuring a next-generation material infused with ProBalance Technology
June 6, 2023 VAUGHAN, Ontario — Bausch + Lomb Corporation has announced the U.S. launch of Biotrue Hydration Boost Contact Lens Rehydrating drops, the first and only preservative-free rehydrating drop in a multi-dose bottle that is indicated to
June 13, 2023 VAUGHAN, Ontario —Bausch + Lomb Corporation has announced the U.S. launch of PreserVision AREDS 2 Formula soft gels plus coenzyme Q10 (CoQ10). Developed as a convenient two-in-one option, PreserVision AREDS 2 Formula eye vitamins plus
June 8, 2023 HEIDELBERG, Germany and CAMBRIDGE, Mass.— Novaliq GmbH, has announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of
May 18, 2023 VAUGHAN, Ontario, and HEIDELBERG, Germany — Bausch + Lomb Corporation and Novaliq GmbH announced that the U.S. Food and Drug Administration (FDA) has approved Miebo, (perfluorohexyloctane ophthalmic solution) formerly known as NOV03,
May 5, 2023 Aliso Viejo, Calif. – Glaukos Corporation announced it has received the “Day 74” notification from the U.S. Food and Drug Administration acknowledging the previously submitted New Drug Application (NDA) for iDose TR (travoprost intraocular
May 5, 2023 SEATTLE – Visus Therapeutics Inc., has presented key topline data from the pivotal Phase 3 BRIO-I clinical trial. The study evaluating the safety and efficacy of BRIMOCHOL PF, a preservative-free ophthalmic solution
April 25, 2023 JENA, Germany, and DUBLIN, Calif. – The U.S. Food and Drug Administration (FDA) has approved the CT LUCIA 621P Monofocal IOL from ZEISS Medical Technology. The aspheric, monofocal, single-piece C-loop IOL features the patented
April 20, 2023 DALLAS – Celanese Corporation, a global specialty materials and chemical company, has entered into an agreement with Glaukos Corporation to supply its VitalDose Drug Delivery Platform for use as a component in
April 19, 2023 BIRMINGHAM, Mich. – MacuHealth has introduced LifeMeter, a portable, non-invasive device that measures the presence of carotenoids in patients. Carotenoids in the macular pigment protect the retina from damage caused by blue
April 18, 2023 FREMONT, Calif. — The U.S. Food and Drug Administration has granted 510(k) clearance to Nova Eye Medical Limited’s new canaloplasty device, iTrack Advance. The newest generation canaloplasty device for canal-based glaucoma surgery
April 11, 2023 WALTHAM, Mass. — The U.S. Food and Drug Administration has approved SYFOVRE (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). From global biopharmaceutical company Apellis
April 11, 2023 NORTH CHICAGO, Ill. – AbbVie, the parent company of Allergan, has announced that the FDA has approved a twice-daily dosing option of Vuity (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia.
